Stereotactic Ablative Radiation Therapy for Multiple Primary Lung Cancer

Liu, Y.; Balter, Peter A; Komaki, Ritsuko; Xu, Qing; Swisher, Stephen G.; Chang, Joe Y.

doi:10.1016/j.ijrobp.2012.07.447

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metachronous multiple primary lung cancer (MMPLC) was defined as those tumors were diagnosed beyond 6 months and fulfilled the above criteria. For MPLC, aggressive local treatment such as stereotactic ablative radiotherapy was reported to achieve median survival of 46.5 months and overall survival of 67% at 3 years and 22.3% at 5 years [ 15 ]. The prognosis of OM is poorer than MPLC in lung cancer.…”

Section: Synchronous Versus Metachronous Oligometastatic Diseasementioning

confidence: 99%

Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer

2012

View full text Add to dashboard Cite

Oligometastatic Non-Small Cell Lung Cancer (NSCLC) presents a unique opportunity for potential curative therapy. Improved cancer staging using PET/CT, MRI, and future cellular and molecular staging with circulating tumor cells and/or molecular markers will identify more patients with truly oligometastasis disease that will benefit from definitive local treatment. Recent development of noninvasive local ablative therapy such as stereotactic radiotherapy makes it possible to eradicate multiple local diseases with minimal side effect. Novel systemic therapy may also control systemic spread and therefore make it possible to improve survival by eliminating local diseases. More research, particularly prospective studies, is ideally randomized studies are needed to validate the concept of oligometastasis.

show abstract

Section: Synchronous Versus Metachronous Oligometastatic Diseasementioning

confidence: 99%